HCW Biologics Inc. has recently issued new shares of common stock as part of a Securities Purchase Agreement with Armistice Capital Master Fund Ltd. The agreement included pre-funded warrants allowing for the purchase of up to 513,140 shares at an exercise price of $0.0001 per share. As of late May, Armistice has exercised portions of these warrants, resulting in the issuance of 177,140 shares on May 15, 126,000 shares on May 22, and 71,000 shares on May 29. Following these transactions, Armistice retains the option to purchase an additional 139,000 shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCW Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-079766), on May 30, 2025, and is solely responsible for the information contained therein.